Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-30
2011-08-30
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S425000, C548S542000
Reexamination Certificate
active
08008341
ABSTRACT:
The present invention relates to benzsulfonamide derivatives of formula I and methods of use thereof. The benzsulfonamide derivatives of the present invention are efficient modulators of the JNK pathway. In particular the benzsulfonamide derivatives of the present invention are selective inhibitors of JNK 2 and 3.
REFERENCES:
patent: 3812144 (1974-05-01), Dietrich et al.
patent: 5744320 (1998-04-01), Sherf et al.
patent: 2004/0077632 (2004-04-01), Halazy et al.
patent: 2004/0077854 (2004-04-01), Halazy et al.
Debnath et al., 4-(4′-Substituted benzoyl)aminobenzenesulphonyl-L(+)-glutamic acids and 5-N-substituted-2-[4′-(4″-substituted benzoyl)aminobenzenesulphonyl]-L-glutamines as potential antineoplastic agents, Indian Journal of Chemistry, vol. 28B, No. 10, pp. 843-847, 1989.
U.S. Appl. No. 10/070,954, filed Sep. 28, 2000, Halazy, et al.
U.S. Appl. No. 10/088,074, filed Oct. 13, 2004, Arkinstall, et al.
U.S. Appl. No. 12/172,485, Jul. 14, 2008, Arkinstall, et al.
U.S. Appl. No. 10/088,090, Jun. 21, 2002, Arkinstall, et al.
U.S. Appl. No. 12/565,988, filed Sep. 24, 2009, Rueckle, et al.
Database HCA ′Online! Chemical Abstracts Service, Columbus, OH, US; abstract No. 125:2165, XP002162517, 1996.
Roger J. Davis: “Signal transduction by the JNK Group of MAP kinases” Cell, vol. 103, pp. 239-252, 2000.
Yi-Rong Chen, et al: “The c-Jun N-terminal kinase pathway and apoptotic signaling” International Journal of Oncology, vol. 16, pp. 651-662, 2000.
YT IP et al: “Signal transduction by the c-Jun N-terminal kinase (JNK) from c-Jun N-terminal kinase (JNK) from inflammation to development” Curr Opin Cell Biol, vol. 10, pp. 205-219, 1998.
S. Leppa et al.: “Diverse functions of JNK signaling and c-Jun in stress response and apoptosis” Oncogene, vol. 18, No. 45, pp. 6158-6162, 1999.
A. Minden et al: “Regulation and function if the JNK subgroup of MAP kinases” Biochim Biophys Acta, vol. 1333, pp. F85-F104, 1997.
A.J. Whitmarsh et al.: “Transcription factor AP-1: regulation by mitogen activated protein kinases signal transduction pathways” J. Mol. Med., vol. 77, pp. 589-607, 1996.
S. Gupta et al.: Selective interation of JNK protein kinase isoforms with trascription factors, The EMBO Journal, vol. 158, No. 11, pp. 2760-2770, 1996.
D. Derek, et al.: “Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene” Nature, vol. 389, pp. 865-876, 1997.
Loel H. Martin et al.: “Development expression in the mouse nervous system of the p493F12 SAP kinase” Molecular Brain Research, vol. 35, pp. 47-57, 1996.
Y. Kumagae et al.: “Human c-Jun N-terminal kinase expression and activation in the nervous system” Molecular Brain Research, vol. 67, pp. 10-17, 1999.
Calin D. Dumitru et al.: “TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway” Cell, vol. 103, pp. 1071-1083, 2000.
Z. Han et al.: “C-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis” The Journal of Clinical Investigation, vol. 108, No. 1, pp. 73-81, 2001.
H. Nishina et al.: “Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-dificent T lymphocytes” Journal of Experimental Medicine, vol. 186, No. 6, pp. 941-953, 1997.
Stephan J. Kempiak et al.: “The Jun kinase cascade is responsible for activating the CD28 response element of the IL-2 promoter: proof of cross-talk with the IB kinase cascade” The Journal of Immunology, vol. 162, pp. 3176-3187, 1999.
S.M. De La Monte et al.: “Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells” J. Alzheimer's Dis., vol. 2, No. 3-4, pp. 261-281, 2000.
X. Zhu: “Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease” Journal of Neurochemistry, vol. 76, pp. 435-441, 2001.
T. Force et al.: “Stress-activated protein kinases in cardiovascular disease” Circulation Research, vol. 78, pp. 947-953, 1996.
S. Kim et al.: “Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery” Circulation, vol. 97, pp. 1731-1737, 1998.
Q. Xu et al.: “Acute hypertension activates mitogen-activated protein kinases in arterial wall” The Journal of Clinical Investigation, vol. 97, No. 2, pp. 508-514, 1996.
M. A. Bogoyevitch, et al.: “Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart” Circulation Research, vol. 79, pp. 163-173, 1996.
CM Pombo et al.: “The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion” J. Biol. Chem., vol. 42, pp. 26546-26551, 1994.
I. Onishi et al.: “Activation of c-Jun N-terminal kinase during ischemia and reperfusion in mouse liver” FEBS Letters, vol. 420, pp. 201-204, 1997.
R. Safirstein: “Renal stress response and acute renal failure” Adv. Ren. Replace Ther., vol. 4, No. 2 Suppl 1, pp. 38-42, 1997.
L. Butterfield, et al.: “C-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation” The Journal of Biological Chemistry, vol. 272, No. 15, pp. 10110-10116, 1997.
M. Hu et al.: JNK2 and JNK3 are p53 N-terminal serine 34 kinases Oncogene, vol. 15, pp. 2277-2287, 1997.
X. Xu et al.: Constitutively activated JNK is associated with HTLV-1 mediated tumorgenesis, Oncogene, vol. 13, pp. 135-142, 1996.
YR Chen et al.: The c-Jun N-terminal kinase pathway and apoptotic signaling Int. J. Oncol., vol. 16, No. 4, pp. 651-662, 2000.
T.C. Harding et al.: “Inhibition of JNK by overexpression of the JNK binding domain of JIP-1 prevents apoptosis in sympathetic neurons” The Journal of Biological Chemistry, vol. 276, No. 7, pp. 4531-4534, 2001.
AF Abdel-Magid et al.: “Reductive amination of aldehves and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductine amination procedures” Journal of Organic Chemistry, vol. 61, pp. 3849-3862, 1996.
L. Xu et al.: “Assess the in-vivo activation of signal transduction pathways with Pathdetect® reporting systems” Strategies, vol. 14, No. 1, pp. 1-3, 2001.
A.M. Manning, et al., “Targeting JNK for Therapeutic Benefit: From Junk to Gold?,” Nature, vol. 2, Jul. 2003, pp. 554-565.
P.A. Scherle, et al., “Kinase Targets in Inflammation,” Emerging Therapeutic Targets, vol. 3, No. 1, 1999, pp. 1-25.
Arkinstall Stephen J.
Biamonte Marco
Camps Montserrat
Church Dennis
Gotteland Jean-Pierre
Coleman Brenda
Merck Serono SA
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Pharmaceutically active benzsulfonamide derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutically active benzsulfonamide derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active benzsulfonamide derivatives as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2721904